SCHEMBL3532064

SCHEMBL3532064

OCCCc1ccc(-c2ccc(CCCO)cc2C(F)(F)F)c(C(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
TSHR P16473 1/20 0.42
GPR84 Q9NQS5 1/20 0.40
S1PR1 P21453 6/20 0.40
PDK2 Q15119 1/20 0.40
KIF11 P52732 1/20 0.38
MMP2 P08253 1/20 0.37
MMP3 P08254 1/20 0.37
CA2 P00918 1/20 0.37
NOTUM Q6P988 1/20 0.36
FFAR4 Q5NUL3 2/20 0.36
DAO P14920 1/20 0.36
S1PR3 Q99500 2/20 0.35
IGF1R P08069 1/20 0.35
ALOX15 P16050 1/20 0.35
PTGES O14684 1/20 0.35
ALOX5 P09917 1/20 0.35
TNKS2 Q9H2K2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL81056 0.84 NR3C2 (0.47) GPR84KIF11FFAR4
SCHEMBL8443136 0.82 GPR84 (0.58) GPR84S1PR1NOTUMIGF1RALOX15
SCHEMBL3532812 0.81 SLC6A2 (0.42) GPR84S1PR1KIF11CA2NOTUM
SCHEMBL79124 0.80 KIF11 (0.56) GPR84KIF11CA2NOTUMFFAR4
SCHEMBL584598 0.79 DAO (0.50) GPR84KIF11CA2NOTUMFFAR4
SCHEMBL16954842 0.78 AR (0.51)
SCHEMBL25896235 0.76 ALOX5 (0.54) S1PR1S1PR3ALOX15PTGESALOX5
SCHEMBL81840 0.72 TAAR1 (0.57) GAACA2CYP4A11
SCHEMBL3637053 0.72 NR3C2 (0.49) GAAPDK2KIF11CA2ALOX5
SCHEMBL6813477 0.72 KDM4E (0.59) GAAGPR84PDK2KIF11CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816385-B2 Dimeric dicarboxylic acid derivatives, their preparation and use HIGH POINT PHARMACEUTICALS, LLC (US) 2010-10-19 US disclosed
US-7816385-B2 Dimeric dicarboxylic acid derivatives, their preparation and use HIGH POINT PHARMACEUTICALS, LLC (US) 2010-10-19 US disclosed
US-7816385-B2 Dimeric dicarboxylic acid derivatives, their preparation and use HIGH POINT PHARMACEUTICALS, LLC (US) 2010-10-19 US disclosed
EP-1578716-A1 DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS NOVO NORDISK A/S (DK) 2005-09-28 EP disclosed
US-20040259950-A1 Novel compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC 2004-12-23 US disclosed
WO-2004056740-A1 DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS NOVO NORDISK A/S (DK) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259950-A1 Novel compounds, their preparation and use PPARG, PPARA, PPARD GLA 1557/4885POLB 1313/4885GAA 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.